Breast cancer test gave Atossa a revenue boost in Q2

08/16/2013 | GenomeWeb Daily News (free registration)

Atossa Genetics posted $326,078 in revenue during the second quarter, up from $223,097 in the same period last year. The increase was fueled by sales of the company's ForeCYTE Breast Health Test, which stratifies patients' breast cancer risk based on mammary aspirate samples.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC